15th Jul 2015 07:59
LONDON (Alliance News) - Biomedical and healthcare technology company NetScientific PLC on Wednesday said the first European patent covering technology from its Glucosense Diagnostics partnership with the University of Leeds has been granted.
NetScientific said the technology uses nano-engineered silica glass with ions that fluoresce when stimulated by a low-power laser. When the glass is in contact with the user's skin, the extent of the fluorescent signal varies in relation to the concentration of glucose in their blood - enabling a direct measurement of glucose levels.
"The award of an important European patent for Glucosense's laser technology is a significant step in preparing the ground for commercial launch within the next three years. We are developing a non-invasive continuous monitoring wearable which may replace implanted devices for people with the severe Type I diabetes; it will also help people with lifestyle induced Type 2 diabetes - a much larger and rapidly growing population," said David Gough, the chairman of Glucosense Diagnostics and the head of European investments and operations for NetScientific.
Shares in NetScientific were up 4.7% to 202.00 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific